Abstract
Simple SummaryMultiple myeloma is a hematological malignancy arising from the proliferation of tumor antibody-producing cells in the bone marrow. In this cancer, tumor growth is facilitated by a permissive bone marrow microenvironment including dysfunctional immune cells that lose their ability to control cancer cells and become “toxic friends”. Immunotherapy is a form of cancer treatment that aims to stimulate the immune system to “fight back” tumor cells. Several immunotherapies have been approved for clinical use and many others are currently under clinical trials. In this review, we focus on current and future immunotherapies used in multiple myeloma with impact on bone marrow immune microenvironment cells, also known as the bone marrow immunome.Despite the improvement of patient’s outcome obtained by the current use of immunomodulatory drugs, proteasome inhibitors or anti-CD38 monoclonal antibodies, multiple myeloma (MM) remains an incurable disease. More recently, the testing in clinical trials of novel drugs such as anti-BCMA CAR-T cells, antibody–drug conjugates or bispecific antibodies broadened the possibility of improving patients’ survival. However, thus far, these treatment strategies have not been able to steadily eliminate all malignant cells, and the aim has been to induce a long-term complete response with minimal residual disease (MRD)-negative status. In this sense, approaches that target not only myeloma cells but also the surrounding microenvironment are promising strategies to achieve a sustained MRD negativity with prolonged survival. This review provides an overview of current and future strategies used for immunomodulation of MM focusing on the impact on bone marrow (BM) immunome.
Highlights
Multiple myeloma (MM) is an incurable hematological malignancy of mature B lymphocytes characterized by the accumulation of clonal plasma cells (PCs) within the bone marrow (BM)
We focus on cu including approved strategies, breakthrough therapies and future appro strategies used for immunomodulation of MM focusing on the impact on including approved strategies, breakthrough therapies and future appro
This study suggests that a combination with daratumumab and all-trans retinoic acid (ATRA) should be explored in future clinical trials
Summary
Multiple myeloma (MM) is an incurable hematological malignancy of mature B lymphocytes characterized by the accumulation of clonal plasma cells (PCs) within the bone marrow (BM). Upregulation of inhibitorymacrophages molecules by tumor c and m and myeloid-derived suppressor cells (MDSCs), Lymphocytes macrophages and antigen-presenting cells, including. Impaired induction of lymphocytes responses, molecules due to a decrease in lymphosion of cytokine tumor antigens or HLA co-stimulatory molecules. Impaired induction of lymphocytes responses, due to ad immunotherapy holds great promise to- treat this hematological disease. Immunotherapy holds great promise treat this hematological including approved strategies, breakthrough therapies and future approaches Ourtargeting increased knowledge of thebeen pathophysiology immunotherapies immune cells have approved for of clinic immunotherapy holds great promise to treat this hematological disease others are currently under clinical trials. We focus on cu immunotherapies targeting immune cells havefocusing been approved for clinic strategies used for immunomodulation of MM on the impact on others are currently under clinical trials. Activation and suppression immune ronment and boosting innate and/or anti-tumor responses
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
